Molecular group:
Leucocyte effector mechanisms and proteases
Molecule/Cell:
Caspase-12
Plasmodium strain:
Plasmodium chabaudi AS
pRBC infection titer:
10^6
Mouse genetic background (Con):
C57BL/6
Level of backcrossing:
Backcrossed for 9 generations
Experimental treatment group (EG):
Casp12 -/-
Lethal infection (Con):
no
Lethal infection (EG):
no
Pathology (Con):
N.I.
Pathology (EG):
N.I.
Parasitemia (EG vs Con):
Decreased peak and decreased recrudescences
Additional phenotypes (EG vs Con):
↓ weight loss at the peak of infection; ↑ serum IFN-g 5-7 days p.i., ↑ serum TNF-a and IL-10 6 days p.i. and ↑ serum IL-18 7 days p.i.; similar serum IgG1 and ↑ IgG2a 21 days p.i.; ↑ production of IFN-g, TNF-a, IL-10 and IL-1b by splenocytes after stimulation with pRBCs for 48h; similar liverpathology 10 days p.i. (serum ALT, liver necrosis and inflammation); similar pro-IL-1b mRNA expression in the spleen 6 days p.i.; ↑ caspase-1 activation in BMDMs after stimulation with pRBCs; similar IkBa and ↑Bcl-xl, cox-2 protein in the spleen 7 days p.i.;
Refs:
Labbé et al., 2010, J Immunol
Hyperlink: